Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

154.32
+3.632.41%
Pre-market: 157.002.68+1.74%05:34 EDT
Volume:402.54K
Turnover:61.64M
Market Cap:9.99B
PE:149.83
High:154.95
Open:152.10
Low:150.82
Close:150.69
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.87
PE(LYR):-75.28

Loading ...

PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications

TIPRANKS
·
Aug 06

Protagonist Therapeutics Grants New Hires Options for 7,300 Shares, RSUs for 1,975 Shares at $136.64 Strike Price

Reuters
·
Aug 05

Protagonist Therapeutics (PTGX) Stock Looks Stretched As A Price Target Boost Lands

Simply Wall St.
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB)

TIPRANKS
·
Jul 22

Protagonist Therapeutics Grants Inducement Equity Awards to New Hires, Sets Option Exercise Price at $135.46

Reuters
·
Jul 17

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Jul 16

Protagonist Therapeutics is Maintained at Overweight by Barclays

Dow Jones
·
Jul 14

Protagonist Therapeutics price target raised to $151 from $119 at Barclays

TIPRANKS
·
Jul 14

Analysts’ Top Healthcare Picks: HCA Healthcare (HCA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
Jul 14

Will Icotyde’s Launch and Rusfertide’s Priority Review Change Protagonist Therapeutics’ (PTGX) Narrative

Simply Wall St.
·
Jul 10

Movement Alert|Protagonist Therapeutics Rises 6.35% in Regular Trading, Truist Raises Price Target to $145

Market Focus
·
Jul 08

Protagonist Therapeutics is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Protagonist Therapeutics Inc : Truist Securities Raises Target Price to $145 from $121

THOMSON REUTERS
·
Jul 07

Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating

MT Newswires Live
·
Jul 07

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following Rusfertide Review Optimism And New Hires – Learn Why

Simply Wall St.
·
Jul 02

Protagonist Therapeutics Grants Inducement Awards for 8,650 Share Options, 2,275 Rsus to New Hires

Reuters
·
Jul 02

Medicare Coverage Could Put These Obesity Drug Stocks In Focus

Simply Wall St.
·
Jun 30

Insider Cashes In: Major Protagonist Therapeutics Stock Sale Shakes Up Investors

TIPRANKS
·
Jun 26

Protagonist Therapeutics Director William D. Waddill Disposes of Common Shares Worth $1.06 Million

Reuters
·
Jun 26

Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan

TIPRANKS
·
Jun 19